Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent Lars Erik KristensenRieke AltenArnold G. Vulto Current Opinion Open access 29 September 2018 Pages: 397 - 404
Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade® Richard MelsheimerMelissa CalmannDonald Neblock Current Opinion Open access 24 August 2018 Pages: 405 - 414
Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Feng HuangZu-chun Luo Systematic Review 10 September 2018 Pages: 415 - 423
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities Beate BittnerWolfgang RichterJohannes Schmidt Review Article Open access 24 July 2018 Pages: 425 - 440
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies Bushra HusainDiego Ellerman Review Article Open access 21 August 2018 Pages: 441 - 464
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates Eshita KheraGreg M. Thurber Review Article 21 August 2018 Pages: 465 - 480
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways Pottayil G. SasikumarMurali Ramachandra Review Article 30 August 2018 Pages: 481 - 497
Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey Rovshan M. IsmailovZaytuna D. Khasanova Original Research Article 17 August 2018 Pages: 499 - 506
SB5: An Adalimumab Biosimilar James E. Frampton Adis Biosimilar Brief 24 September 2018 Pages: 507 - 510
ABP 980: A Trastuzumab Biosimilar Sohita Dhillon Adis Biosimilar Brief 27 September 2018 Pages: 511 - 514
PF-05280014: A Trastuzumab Biosimilar Julia Paik Adis Biosimilar Brief 03 October 2018 Pages: 515 - 518
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?” Christopher J. WebsterGillian R. Woollett Letter to the Editor Open access 16 August 2018 Pages: 519 - 521
Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?” Francois-Xavier Frapaise Letter to the Editor 16 August 2018 Pages: 523 - 523
Correction to: GP2015: An Etanercept Biosimilar Emma D. Deeks Correction Open access 01 August 2018 Pages: 525 - 525
